Healthcare

CITY.PK
JNJ.N
PFE.N

BRIEF-Cytos Biotechnology H1 net income turns to profit of CHF 7.77 mln

* Net income was 7.77 million Swiss francs ($8.07 million)in first half-year of 2015 (compared to a net loss of 23.44 million Swiss francs in same period in 2014)

11:48am EDT

UPDATE 2-Humana says medical costs cut into second-quarter profit

July 29 - Health insurer Humana Inc, which earlier this month agreed to be bought by Aetna Inc for $37 billion, on Wednesday reported a rise in a key medical cost metric that missed analyst expectations.

Express Scripts says costly new cholesterol drugs could wreak havoc

July 29 - Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients.

BRIEF-Medivir starts clinical trial for treatment of hepatitis C

* Medivir announces start of a phase i clinical trial of the nucleotide polymerase inhibitor al-704 for treatment of hepatitis c

11:08am EDT

BRIEF-Polmed gives further details on deal with TU Zdrowie

* Agrees further terms of provision of health care services following deal from May 28 with Towarzystwo Ubezpieczen Zdrowie SA (TU Zdrowie)

10:48am EDT

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00
Provider: Renaissance Capital
$92.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.